Abstract 184P
Background
Pancreatic cancer remains a highly lethal malignancy with limited treatment options for metastatic and recurrent cases. Nanoliposomal-irinotecan and fluorouracil with leucovorin (NFF) has emerged as the standard treatment following gemcitabine-based regimens. However, the relationship between treatment outcomes and neutropenia in pancreatic cancer has not been thoroughly investigated.
Methods
In this retrospective study, we analyzed data from 161 patients with pancreatic cancer treated with NFF. Neutropenia was assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) cutoffs: Cutoff A (CTCAE Grade 0 versus Grade 1–4), Cutoff B (Grade 0–1 versus Grade 2–4), and Cutoff C (Grade 0–2 versus Grade 3–4). The primary endpoint was overall survival (OS), while secondary endpoints included response rate (RR), progression-free survival (PFS), and relative dose intensity (RDI).
Results
Among the 161 patients, 93/8/22/30/8 had Grade 0/1/2/3/4 neutropenia, respectively. Baseline patient characteristics, including white blood cell (WBC) count, neutrophil count, lymphocyte count, C-reactive protein (CRP) levels, and FU RDI, exhibited significant differences (p<0.05) between two groups separated by Cutoff A and Cutoff B. Additionally, WBC count, neutrophil count, and FU RDI differed significantly (p<0.05) at Cutoff C. Fisher’s exact test revealed significant differences (p<0.05) in RR at Cutoff C, with the odds ratio of Cutoff C being the greatest, followed by Cutoff B and A. Regarding OS, there were significant differences at Cutoff A (hazard ratio (HR), 0.65; 95% CI, 0.44–0.94; p<0.05) and Cutoff B (HR, 0.63; 95% CI, 0.43–0.92; p<0.05), but not at Cutoff C (HR, 0.73; 95% CI, 0.47–1.14; p=0.16). Furthermore, there were significant differences in PFS at Cutoff A and B (p<0.05). Cox regression analysis indicated that neutropenia was significantly associated with OS at Cutoff A and B (adjusted p<0.05).
Conclusions
NFF-induced neutropenia exhibits significant potential as both a predictive factor for treatment response and a prognostic factor for OS in patients with pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract